HRMY HARMONY BIOSCIENCES HLDGS IN revenue, earnings and financials

For the quarter ended June 30, 2026, HARMONY BIOSCIENCES HLDGS IN reported revenue of $261M (up 30.3% from a year earlier), net income of $75.4M and diluted EPS of $1.28; over the last four quarters revenue was $960M and net income $181M; for the fiscal year ended December 2025 revenue was $868M, up 21.5% on the year before.

HRMY annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $868M, gross profit $670M, operating income $208M, net income $159M (margin 18.3%), EPS $2.71
• Fiscal year ended Dec 2024: revenue $715M, gross profit $558M, operating income $191M, net income $145M (margin 20.4%), EPS $2.51
• Fiscal year ended Dec 2023: revenue $582M, gross profit $461M, operating income $192M, net income $129M (margin 22.1%), EPS $2.13
• Fiscal year ended Dec 2022: revenue $438M, gross profit $354M, operating income $120M, net income $181M (margin 41.4%), EPS $2.97
• Fiscal year ended Dec 2021: revenue $305M, gross profit $250M, operating income $87.5M, net income $34.6M (margin 11.3%), EPS $0.58

HRMY quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $261M (up 30.3% year over year), net income $75.4M, EPS $1.28
• Quarter ended Mar 31, 2026: revenue $215M (up 16.6% year over year), net income $32.5M, EPS $0.55
• Quarter ended Dec 31, 2025 (from the annual report): revenue $244M (up 21.1% year over year), net income $22.5M, EPS $0.38
• Quarter ended Sep 30, 2025: revenue $239M (up 28.7% year over year), net income $50.9M, EPS $0.87
• Quarter ended Jun 30, 2025: revenue $200M (up 16.0% year over year), net income $39.8M, EPS $0.68
• Quarter ended Mar 31, 2025: revenue $185M (up 19.5% year over year), net income $45.6M, EPS $0.78
• Quarter ended Dec 31, 2024 (from the annual report): revenue $201M (up 19.5% year over year), net income $49.5M, EPS $0.85
• Quarter ended Sep 30, 2024: revenue $186M (up 16.1% year over year), net income $46.1M, EPS $0.79
• Quarter ended Jun 30, 2024: revenue $173M (up 28.8% year over year), net income $11.6M, EPS $0.20
• Quarter ended Mar 31, 2024: revenue $155M (up 29.8% year over year), net income $38.3M, EPS $0.67
• Quarter ended Dec 31, 2023 (from the annual report): revenue $168M (up 31.3% year over year), net income $26.6M, EPS $0.46
• Quarter ended Sep 30, 2023: revenue $160M (up 36.7% year over year), net income $38.5M, EPS $0.63
• Quarter ended Jun 30, 2023: revenue $134M (up 25.4% year over year), net income $34.3M, EPS $0.56
• Quarter ended Mar 31, 2023: revenue $119M (up 39.6% year over year), net income $29.5M, EPS $0.48
• Quarter ended Dec 31, 2022 (from the annual report): revenue $128M (up 40.7% year over year), net income $48.5M, EPS $0.79
• Quarter ended Sep 30, 2022: revenue $117M (up 45.2% year over year), net income $87.9M, EPS $1.44
• Quarter ended Jun 30, 2022: revenue $107M (up 45.0% year over year), net income $23.5M, EPS $0.39
• Quarter ended Mar 31, 2022: revenue $85.3M (up 43.0% year over year), net income $21.5M, EPS $0.35
• Quarter ended Dec 31, 2021 (from the annual report): revenue $91.2M, net income $22.7M, EPS $0.38
• Quarter ended Sep 30, 2021: revenue $80.7M, net income −$9.62M, EPS −$0.17

HRMY cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $348M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $220M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $219M, share buybacks $100M
• Fiscal year ended Dec 2022: operating cash flow $144M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $98.6M, share buybacks n/a

HRMY balance sheet

• Jun 30, 2026: cash $550M, total assets $1.37B, total liabilities $374M, shareholders' equity $999M, long-term debt $134M
• Mar 31, 2026: cash $589M, total assets $1.27B, total liabilities $361M, shareholders' equity $910M, long-term debt $139M
• Dec 31, 2025: cash $753M, total assets $1.27B, total liabilities $401M, shareholders' equity $870M, long-term debt $144M
• Sep 30, 2025: cash $647M, total assets $1.21B, total liabilities $373M, shareholders' equity $835M, long-term debt $149M
• Jun 30, 2025: cash $546M, total assets $1.11B, total liabilities $335M, shareholders' equity $773M, long-term debt $153M
• Mar 31, 2025: cash $489M, total assets $1.06B, total liabilities $335M, shareholders' equity $721M, long-term debt $158M
• Dec 31, 2024: cash $453M, total assets $999M, total liabilities $340M, shareholders' equity $659M, long-term debt $163M
• Sep 30, 2024: cash $387M, total assets $928M, total liabilities $331M, shareholders' equity $597M, long-term debt $168M

What is HRMY's revenue?

HARMONY BIOSCIENCES HLDGS IN reported $960M of revenue over its last four quarters, through June 30, 2026.

Is HRMY profitable?

Yes. HARMONY BIOSCIENCES HLDGS IN earned $181M over the last four quarters.

What is HRMY's EPS?

Diluted earnings per share over the last four quarters were $3.08; $1.28 in the latest quarter.

HRMY ownership and insider trades · All stocks